The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 2, 1999, Pages 259-263

  Borkow, Gadi ^a   Arion, Dominique ^a   Wainberg, Mark A ^a   Parniak, Michael A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0032992656     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.2.259     Document Type: Article

References (42)

1. Arion, D., N. Kaushik, S. McCormick, G. Borkow, and M. A. Parniak, 1998. Phenotypic mechanism of HIV-1 resistance to 3′-azido, 3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37: 15908-15917.
2. Lys3 as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/ template-switching reaction. J. Biol. Chem. 269:14672-14680.
3. Balzarini, J., M. J. Perez-Perez, S. Velazquez, A. San-Felix, M.-J. Camarasa, E. De Clercq, and A. Karlsson. 1995. Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives). Proc. Natl. Acad. Sci. USA 92:5470-5474.
4. Balzarini, J., W. G. Brouwer, D. C. Dao, E. M. Osika, and E. De Clercq. 1996. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob. Agents Chemother. 40:1454-1466.
5. Balzarini, J., H. Pelemans, S. Aquaro, C. F. Perno, M. Witvrouw, D. Schols, E. De Clercq, and A. Karlsson. 1996. Highly favourable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC781 and UC82 as inhibitors of human immunodeficiency virus type 1 (HIV-1) replication. Mol. Pharmacol. 50:394-401.
6. Barnard, J., G. Borkow, and M. A. Parniak. 1997. The thiocarboxanilide UC781 is a tight-binding nonnucleoside inhibitor of HIV-1 reverse transcriptase. Biochemistry 36:7786-7792.
7. Borkow, G., J. Barnard, T. M. Nguyen, A. Belmonte, M. A. Wainberg, and M. A. Parniak. 1997. Chemical harriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J. Virol. 71: 3023-3030.
8. Borkow, G., D. Arion, N. Kaushik, and M. A. Parniak. Unpublished data.
9. Buckheit, R. W., M. J. Snow, V. Fliakas-Boltz, T. L. Kinjerski, J. D. Russell, L. A. Pallansch, W. G. Brouwer, and S. S. Yang. 1997. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. 41:831-837.
10. Chou, T.-C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
11. Cox, S. W., J. Albert, J. Wahlberg, M. Uhlen, and B. Wahren. 1992. Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1. AIDS Res. Hum. Retroviruses 8:1229-1234.
12. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, and J. O. Kahn. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
13. De Clercq, E. 1993. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 13:229-258.
14. Ding, J., K. Das, H. Moereels, L. Koymans, K. Andries, P. A. Janssen, S. H. Hughes, and E. Arnold. 1995. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol. 2:407-415.
15. Fletcher, R. S., G. Holleschak, E. Nagy, D. Arion, G. Borkow, Z. Gu, M. A. Wainberg, and M. A. Parniak. 1996. Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase. Prot. Expression Purif. 7: 27-32.
16. Gao, Q., Z. Gu, M. A. Parniak, X. Li, and M. A. Wainberg. 1992. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-dcoxythymidine and 2′,3′-dideoxyinosine. J. Virol. 66:12-19.
17. Gao, Q., Z. Gu, H. Salomon, K. Nagai, M. A. Parniak, and M. A. Wainberg. 1994. Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1. Arch. Virol. 136:111-122.
18. Goldman, M. E., J. H. Nunberg, J. A. O'Brien, J. C. Quintero, J. M. Schlief, K. F. Freund, S. L. Gaul, W. S. Saari, J. S. Wai, J. M. Hoffman, P. S. Anderson, D. J. Hupe, E. A. Emini, and A. M. Stern. 1991. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA 88:6863-6867.
19. Goody, R. S., B. Muller, and T. Restle. 1991. Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo. FEBS Lett. 291:1-5.
20. Gu, Z., R. S. Fletcher, E. J. Arts, M. A. Wainberg, and M. A. Parniak. 1994. The K65R mutant reverse transcriptase associated with HIV-1 resistance to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J. Biol. Chem. 269:28118-28122.
21. Gu, Z., E. J. Arts, M. A. Parniak, and M. A. Wainberg. 1995. Mutated K65R recombinant HIV-1 reverse transcriptase shows diminished chain termination in the presence of 2′,3′-dideoxycytidine-5′-triphosphate and other drugs. Proc. Natl. Acad. Sci. USA 92:2760-2764.
22. Kellam, P., C. A. B. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
23. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
24. Kopp, E. B., J. J. Miglietta, A. G. Shrutkowski, C.-K. Shih, P. M. Grob, and M. T. Skoog. 1991. Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone. BI-RG-587, using a heteropolymeric template. Nucleic Acids Res. 19:3035-3039.
25. Lacey, S. F., J. E. Reardon, E. S. Furfine, T. A. Kunkel, K. Bebenek, K. A. Eckcrt, S. D. Kemp, and B. A. Larder. 1992. Biochemical studies on the reverse transcriptase and RNase H activities from HIV strains resistant to 3′-azido-3′-denxythymidine. J. Biol. Chem. 267:15789-15794.
26. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
27. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
28. McMahon, J. B., R. W. Buckheit, Jr., R. J. Gulakowski, M. J. Currens, D. T. Vistica, R. H. Shoemaker, S. F. Stinson, J. D. Russell, J. P. Bader, V. L. Narayanan, R. J. Schultz, W. G. Brouwer, E. E. Felauer, and M. R. Boyd. 1996. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. J. Pharmacol. Exp. Ther. 276:298-305.
29. Mellors, J. W., G. E. Dutchman, G. J. Im, E. Tramontano, S. R. Winkler, and Y. C. Cheng. 1992. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41:446-451.
30. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. T. Skoog. J. C. Wu, C.-K. Shin, K. Eckner, S. Hattox, J. Adams, A. S. Rosehthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan. 1990. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
31. Mitsuya, H., R. Yarchoan, and S. Broder. 1990. Molecular targets for AIDS therapy. Science 249:1533-1544.
32. Montaner, J. S., J. Singer, M. T. Schechter, J. M. Raboud, C. Tsoukas, M. O'Shaughnessy, J. Ruedy, K. Nagai, H. Salomon, B. Spira, and M. A. Wainberg. 1993. Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS 7:189-196.
33. 3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group. Ann. Intern. Med. 123:561-571.
34. Pauwels, R., K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M. A. Janssen, E. De Clercq, and P. A. J. Janssen. 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474.
35. Rooke, R., M. Tremblay, H. Soudeyns, L. DeStephano, X.-J. Yao, M. Fanning, J. S. Montaner, M. O'Shaughnessy, K. Gelmon, C. Tsoukas, and M. A. Wainberg. 1989. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 3:411-415.
36. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
37. Smerdon, S. J., J. Jäger, L. A. Kohlstaedt, A. J. Chirino, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1994. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 91:3911-3915.
38. Tudor-Williams, G., M. H. St. Clair, R. E. McKinney, M. Maha, E. Walter, S. Santacroce, M. Mintz, K. O'Donnell, T. Rudoll, and C. L. Vavro. 1992. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 339: 15-19.
39. Wainberg, M. A., M. Tremblay, R. Rooke, N. Blain, H. Soudeyns, M. A. Parniak, X.-J. Yao, X. Li, M. Fanning, J. S. G. Montaner, M. O'Shaughnessy, C. Tsoukas. J. Falutz, M. Stern, B. Belleau, and J. Ruedy. 1991. Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study. Ann. N. Y. Acad Sci. 616:346-355.
40. Wainberg, M. A., W. C. Drosopoulos, H. Salomon, M. Hsu, G. Borkow, M. A. Parniak, Z. Gu, Q. Song, J. Manne, S. Islam, G. Castriota, and V. R. Prasad. 1996. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:1282-1285.
41. Yang, S. S., V. Fliakas-Boltz, J. P. Bader, and R. W. Buckheit, Jr. 1995. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity. Leukemia 9:S75-S85.
42. Yao, X.-J., M. A. Wainberg, and M. A. Parniak. 1992. Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. Virology 187:56-62.